Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5200883 | 1.00 | ATM (0.59) | ATMCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL764093 | 1.00 | ATM (0.59) | ATMCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL242328 | 1.00 | ATM (0.59) | ATMCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL55610 | 1.00 | ATM (0.59) | ATMCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL116439 | 1.00 | ATM (0.59) | ATMCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL55611 | 1.00 | ATM (0.59) | ATMCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL873280 | 1.00 | ATM (0.59) | ATMCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL312687 | 1.00 | ATM (0.59) | ATMCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL4275881 | 0.98 | ATM (0.57) | ATMCYP1A2POLBCYP3A4CYP2C19 | |
| Ammonia Solution, Strong SCHEMBL29062671 | 0.98 | ATM (0.57) | ATMCYP1A2POLBCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 680 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114280133-B | Analytical reagent and method for identifying proline and derivative isomer | 宁波大学 | 2024-07-05 | — | — | CN | claimed |
| CN-117567498-A | Sodium hydride suspension and application thereof in flow chemical reaction | 武汉药明康德新药开发有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-114797984-B | Heterogeneous chiral bifunctional catalyst and preparation method and application thereof | 东南大学 | 2023-08-25 | — | — | CN | claimed |
| CN-114797984-A | Heterogeneous chiral dual-function catalyst and preparation method and application thereof | 东南大学 | 2022-07-29 | — | — | CN | claimed |
| CN-114280133-A | Analytical reagent and method for identifying proline and derivative isomer | 宁波大学 | 2022-04-05 | — | — | CN | claimed |
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4676929-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2026-01-14 | — | — | EP | disclosed |
| CN-121248608-A | Preparation method of absolute chiral 2-hydroxy hexahydro-1H-pyridine-7 a-carboxylic acid | 韶远科技（上海)有限公司 | 2026-01-02 | — | — | CN | disclosed |
| EP-4638447-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | Dark Blue Therapeutics Ltd (GB) | 2025-10-29 | — | — | EP | disclosed |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | ARTIOS PHARMA LIMITED (GB) | 2025-07-15 | — | — | US | disclosed |
| WO-2025124444-A1 | USE OF HYDROXYPROLINE AND DERIVATIVE THEREOF, BIOLOGICAL HERBICIDE, BROAD-SPECTRUM HERBICIDE, AND WEED CONTROL METHOD | 三亚市国家耐盐碱水稻技术创新中心 | 2025-06-19 | — | — | WO | disclosed |
| US-12331059-B2 | Class of functional molecules targeting proteolysis pathways, preparation and application thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2025-06-17 | — | — | US | disclosed |
| US-5057506-A | Anticonvulsants, antispasmodic and antischemic agents | CIBA-GEIGY CORPORATION (US) | 1991-10-15 | — | — | US | disclosed |
| EP-0203891-B1 | CERTAIN PHOSPHONIC ACIDS AND DERIVATIVES | CIBA-GEIGY AG (CH) | 1991-05-15 | — | — | EP | disclosed |
| US-4906621-A | Certain 2-carboxypiperidyl-alkylene phosphonic acids and esters thereof useful for the treatment of disorders responsive to N-methyl-D-aspartate receptor blockade | CIBA-GEIGY CORPORATION (US) | 1990-03-06 | — | — | US | disclosed |
| US-4898854-A | NERVOUS SYSTEM DISORDERS | CIBA-GEIGY CORPORATION (US) | 1990-02-06 | — | — | US | disclosed |
| EP-0337637-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
| EP-0334244-A2 | Bradykinin Antagonist Peptides | THE PROCTER & GAMBLE COMPANY (US) | 1989-09-27 | — | — | EP | disclosed |
| EP-0203891-A2 | Certain phosphonic acids and derivatives | CIBA-GEIGY AG (CH) | 1986-12-03 | — | — | EP | disclosed |
| US-4501901-A | Method for making substituted prolines | E. R. SQUIBB & SONS, INC. (US) | 1985-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331059-B2 | Class of functional molecules targeting proteolysis pathways, preparation and application thereof | XIAP, ADRM1, PSMB1 | ATM 1747/4885CYP1A2 3752/4885POLB 1584/4885 |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | SDHA, DPYD, TP53 | ATM 468/4885CYP1A2 104/4885POLB 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.